The cumulative figures cover tirzepatide, semaglutide, and liraglutide—three incretin-based compounds now prescribed to approximately 1.6 million adults in Great Britain for obesity and type 2 diabetes management.
Quantifying the signal
The MHRA's Yellow Card scheme operates as a decentralized early-warning system. Any patient, caregiver, pharmacist, or physician can submit an adverse event report without establishing a direct biological link between product and outcome. The agency has indicated that raw reporting volume correlates primarily with prescription prevalence and media-driven awareness rather than a sudden deterioration in class-level safety.
Breakdown by compound:
- Tirzepatide (Mounjaro, Eli Lilly): 106,189 adverse reactions, 120 suspected deaths
- Semaglutide (Wegovy, Ozempic; Novo Nordisk): 48,089 reactions, 59 suspected deaths
- Liraglutide (Saxenda, Novo Nordisk): 4,491 events, 37 fatalities
The denominator carries quantifiable weight. A treated population of 1.6 million, frequently presenting with preexisting cardiovascular disease, hypertension, and metabolic syndrome, carries baseline mortality independent of any pharmacological intervention.
Documented pathophysiology
Spontaneous reports cannot establish causation independently. Formal judicial inquests, however, have begun documenting specific clinical mechanisms. Senior Coroner Philip Spinney in Devon confirmed that a GLP-1 receptor agonist contributed to the death of 66-year-old Paula Owen, who died of severe acute pancreatitis in Plymouth. The determination constitutes one of the earliest coroner findings in England linking incretin therapy directly to fatal pancreatic inflammation.
Regulatory records document recurring patterns of severe gastrointestinal disturbance and acute pancreatitis across the therapeutic class.
Mitigation framework
The MHRA confronts a dual operational burden: separating genuine adverse drug reactions from background comorbidities while curbing unmonitored access through private prescribing channels and an illicit online trade in counterfeit injection pens. Clinicians managing patients on GLP-1 therapy should establish the following verification thresholds before initiation or continuation:
1. Prescriber credentials and registration with the General Medical Council or equivalent regulatory body.
2. Device source verification. Counterfeit pens circulating through unregulated online vendors present distinct, unquantified risk.
3. Documented baseline assessment of cardiovascular status and pancreatic history.
4. Structured protocols for Yellow Card submission of any suspected adverse event.
The variance between raw reporting volume and verified causation remains substantial. The 216 suspected fatalities constitute a pharmacovigilance signal warranting continued surveillance. The Devon coroner's finding establishes that fatal mechanisms exist within the therapeutic class. Population-level incidence, calibrated against the 1.6 million treated adults and their preexisting comorbidity burden, does not currently indicate class-wide toxicity. Practitioners should counsel patients on the distinction between spontaneous report accumulation and verified clinical risk, while documenting preexisting comorbidities that independently elevate baseline mortality.